206. Fragile X syndrome Clinical trials / Disease details

Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01325740 (ClinicalTrials.gov)	May 2011	28/3/2011	A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of STX107 in Adults With Fragile X Syndrome	Fragile X Syndrome	Drug: STX107	Seaside Therapeutics, Inc.	NULL	Suspended	18 Years	50 Years	Male	16	Phase 2	United States
2	NCT00965432 (ClinicalTrials.gov)	September 2009	24/8/2009	A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107	A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy, Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107	Fragile X Syndrome	Drug: STX107	Seaside Therapeutics, Inc.	National Institutes of Health (NIH)	Completed	18 Years	50 Years	Male	40	Phase 1	United States